FULGENT GENETICS DL-,0001 Logo
US3596641098
A2AS4N
FLGT

FULGENT GENETICS DL-,0001

Forecast

The analysts' average price target is €17.32 (-21.27%). The median is €17.32 (-21.27%).

Buy
  6
Hold
  3
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Fulgent: phase‑2 data on cancer drug FID‑007 show 60% response rate

    Fulgent published an abstract of the open‑label, randomized phase‑2 study of FID‑007 in combination with cetuximab, which will be presented at the ASCO meeting on June 1, 2026. Among 42 evaluable patients with recurrent/metastatic head and neck squamous cell carcinoma, the objective response rate was 60% and median progression‑free survival was 7.2 months; median duration of response was 7.4 months. The safety profile consisted mostly of grade‑1/2 events; grade‑3/4 events included neutropenia and anemia, and in arm B a treatment‑related death due to pneumonia was reported. According to the analysis, Fulgent has more liquid assets than liabilities, but the stock has fallen 45% over the past six months and is considered undervalued. » More on de.investing.com


  • Fulgent misses Q1 revenue forecast after customer loss, positive FID‑007 data give hope

    Fulgent reported Q1 2026 revenue of $71.1 million and a loss per share of $0.36, both well below analyst expectations; the company attributed the decline mainly to its largest customer moving to internal capacities. Despite margin pressure and negative operating cash flow, strong Phase‑2 data for FID‑007 stood out (ORR 51%, median PFS 7.8 months), and management plans an FDA meeting and the preparation of a Phase‑3 protocol. Fulgent maintains its full‑year guidance of $350 million, emphasizes its liquid balance sheet and is banking on recent acquisitions and the therapeutic pipeline, but must overcome cash burn, margin pressure and stabilize revenue. » More on de.investing.com


  • Fulgent reports Q4 results: stock falls after departure of major customer

    Fulgent reported Q4/2025 revenue of $83m (below expectations) and surprised with non‑GAAP EPS of $0.16. The stock plunged about 22% in premarket trading after it emerged that the largest customer (22% of 2025 revenue) will bring testing in‑house. The company forecasts 2026 revenue of $350m and a non‑GAAP loss per share of ($1.45), but expects strong headwinds through mid‑2026. Fulgent highlights a strong balance sheet ($336.1m in cash and marketable securities as of 12/31/2025) and progress in its therapeutic pipeline around FID‑007 as a long‑term value driver. » More on de.investing.com


  • Fulgent Genetics raises full-year revenue forecast after strong quarter

    Fulgent Genetics reported first-quarter revenue of $84.1 million, beating expectations. The company raised its full-year forecast to $325 million and reported improved non-GAAP gross margins in the mid-40% range. Cash on hand is expected to be around $800 million by the end of 2025 to fund investments in technology, M&A and therapeutics; significantly higher therapeutics spending is planned for 2026 and the start of a Phase 3 trial is expected. Operationally, Fulgent is focusing on efficiency gains, expanding sales and broadening biopharma services, while partnerships are developing more slowly than expected. » More on de.investing.com


  • Fulgent Genetics: positive phase-2 data in head and neck cancer

    Fulgent Genetics reported preliminary phase-2 data for FID-007 in combination with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma. Among 35 evaluable patients the objective response rate was 51% (44% at 75 mg/m², 59% at 125 mg/m²) and median progression-free survival was 7.8 months versus a historical 2.3 months. The treatment showed a favorable safety profile with 6% serious treatment-related adverse events; common grade-3 events were lymphopenia (19%), neutropenia (17%) and anemia (8%). Fulgent also has a solid balance sheet, reported Q2 revenue of $81.8m above expectations and received an upgrade from UBS with a price target raised to $30.00. » More on de.investing.com

Financials

In the last quarter, FULGENT GENETICS DL-,0001 had revenue of €79.82M and net profit of -€11.61M

(EUR) September 2026
YoY
Revenue 79.82M 11.42%
Gross profit 28.2M 6.80%
Net profit -11.61M 106.21%
EBITDA -6.37M 9,614.66%

Fundamentals

Metric Value
Market capitalization
€614.15M
Number of shares
27.94M
52-week high/low
€28.29 - €12.27
Dividends No
Beta
1.00
P/E ratio
-7.81
PEG ratio
0.12
P/B ratio
0.67
P/S ratio
2.04

Company profile

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Name
FULGENT GENETICS DL-,0001
CEO
Ming Hsieh
Headquarters El Monte, ca
USA
Website
Sector
Health Care
Industry
Health Care Providers & Services
IPO
09/29/2016
Employees 1,315

Ticker symbols

Exchange Symbol
NASDAQ
FLGT
Frankfurt
7F0.F
DĂĽsseldorf
7F0.DU
MĂĽnchen
7F0.MU
🍪

Parqet  uses cookies. Learn more